To better assess MASLD in T2DM, this study developed a novel marker derived from the CTI calculation formula, combining hsCRP and AIP, termed the “Hypersensitive C-reactive protein-atherogenic Index” (CAI). The gene discussed is CRP; the disease is type 2 diabetes mellitus.